

REC'D 30 JUL 2004

WIPO

PA 1179326

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

June 04, 2004


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/486,795

FILING DATE: July 11, 2003

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



T. Lawrence

T. LAWRENCE

Certifying Officer

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

07/16/2003 LWDNDIM1 00000019 231703 60486795
01 FC:1005 160.00 DA

PTO-1556
(5/87)

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

EV 121018469US

INVENTOR(S)					
Given Name (first and middle [if any])	Family Name or Surname		Residence (City and either State or Foreign Country)		
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
METHOD FOR ADMINISTRATION AND FORMULATION					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		007470		→ Place Customer Number Bar Code Label here	
OR		Type Customer Number here			
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		17		<input type="checkbox"/> CD(s), Number	
<input type="checkbox"/> Drawing(s) Number of Sheets				<input checked="" type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76				claims - 3 pgs.; abstract - 1 pgs.	
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:				23-1703	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.				\$160.00	
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

John M. Genova

TYPED or PRINTED NAME John M. Genova

TELEPHONE 212-819-8200

Date 07/11/2003

REGISTRATION NO.
(if appropriate)
Docket Number:

32,224

1103326-0728

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (05-03)
Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 160

Complete if Known

Application Number TBA
Filing Date TBA
First Named Inventor
Examiner Name
Art Unit
Attorney Docket No. 1103326-0728

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 23-1703
Deposit Account Name White & Case

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Small Entity Fee Code	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	160
SUBTOTAL (1)			(\$ 160

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple Dependent	-3** =	X	

Large Entity Fee Code	Small Entity Fee Code	Fee Description	Fee Paid
1202 18	2202 9	Claims in excess of 20	
1201 84	2201 42	Independent claims in excess of 3	
1203 280	2203 140	Multiple dependent claim, if not paid	
1204 84	2204 42	** Reissue independent claims over original patent	
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Small Entity Fee Code	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 65	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1808 180	1808 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type) John M. Genova Registration No. 32,224 Telephone 212-819-8200
Signature [Signature] Date July 11, 2003

WARNING: Information in this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<p>"Express Mail" Label No. <u>BV121018469US</u> Date of Deposit: <u>July 11, 2003</u>. I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Provisional Patent Application; Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450</p> <p><u>BERNARD MAYS</u> (Type or print name of person mailing paper or fee)</p> <p><u>Bernard Mays</u> (Signature of person mailing paper or fee)</p>
--

RE: Title: METHOD FOR ADMINISTRATION AND FORMULATION
Inventors:
Our Ref.: 1103326-0728

The following are enclosed:

- PTO/SB/16 – Provisional Application for Patent Cover Sheet;
- PTO/SB/17 – Fee Transmittal authorizing charge to a Deposit Account;
- Provisional patent application:
 - Specification: 17 pages;
 - Claims: 3 pages;
 - Abstract: 1 page; and
- Return postcard.

Respectfully submitted,

John M. Genova

John M. Genova

Reg. No. 32,224

Attorney for Applicant(s)

Attorney's Direct Telephone: 212-819-8832

Customer No. 007470

(212) 819-8200

Enclosures

Applicant: AstraZeneca AB
S-151 85 Södertälje
Sweden

Title: METHOD FOR ADMINISTRATION AND
FORMULATION

Reference: 101161-1US

Inventors:

METHOD FOR ADMINISTRATION AND FORMULATION

Field of the invention.

5 The present invention relates to a method for oral administration of an acid labile heterocyclic compound with gastric acid inhibitory effect, in the following referred to as a proton pump inhibitor compound, and a pharmaceutical composition comprising a proton pump inhibitor compound. The method and composition are especially aimed for treatment of patients with difficulties to swallow and for pediatric patients. Furthermore, the present
10 invention refers to a method for the manufacturing of said composition and its use in medicine.

Background of the invention and prior art.

15 Proton pump inhibitor compounds having effect as H^+K^+ -ATPase inhibitors are for instance compounds known under the generic names omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole.

These active substances are useful for inhibiting gastric acid secretion in mammals and
20 man. In a more general sense, they may be used for prevention and treatment of gastric acid related diseases in mammals and man, including e.g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with
25 symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. They may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre-and postoperatively to prevent acid aspiration of gastric acid and to prevent and treat stress ulceration. Further, they may be useful for prevention and treatment of irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), asthma,
30 laryngitis, Barret's syndrome, sleep apnea, sleep disturbance, psoriasis as well as in the treatment of Helicobacter infections and diseases related to the above.

These active compounds are, however, susceptible to degradation/transformation in acidic and neutral media. The degradation is catalyzed by acidic compounds and is stabilized in mixtures with alkaline compounds. The stability of the active substances is also affected by moisture, heat, organic solvent and to some degree by light.

With respect to the stability properties of the active substances, it is obvious that an oral dosage form should be protected from contact with the acidic gastric juice or comprise suitable components to neutralise the acidic gastric juice so that the active substance can be transferred in intact form to that part of the gastrointestinal tract where pH is near neutral and where rapid absorption can occur.

A pharmaceutical oral dosage form of such an acid labile H^+K^+ -ATPase inhibitor is best protected from contact with acidic gastric juice by an enteric coating layer. Commonly used solid dosage forms for oral administration are capsules and tablets comprising a multitude of enteric coated pellets of the active ingredient. For instance the following US patents, US 4,853,230, US 4,786,505, US 5,817,338 and US 5,753,265 describe suitable enteric coated preparations. Said preparations contain a core comprising the active ingredient or an alkaline salt thereof, optionally together with an alkaline reacting material, the core is layered with a separating layer and an enteric coating layer. The separating layer may be an optional feature. In order to further enhance the storage stability the prepared formulation may optionally be packed with a desiccant.

However, tablets and capsules are less suitable for administration to patients with difficulties to swallow and for pediatric use. Several of the proton pump inhibitors can be administered orally after dispersion in an aqueous liquid, such as water, fruit juice and fruit sauce. Some of the marked proton pump inhibitors such as omeprazole and lansoprazole, are approved for administration via nasogastric tube, but there is still a need for improvement. For administration via tube, the content of a Prevacid ® capsule, i.e. the enteric coated pellets of lansoprazole, will be emptied into 40 mL apple juice and injected through a nasogastric tube. However, only tubes with a relatively large inner diameter, e.g. CH16 (CH= Cherrier), are suitable for this administration.

The tableted dosage form described in US 5,817,338, which is marked outside USA under the trade name Losec® MUPS®, is also suitable for administration via naso-gastric tube after being dispersed in water to a suspension, whereas the product marked in USA under the trade name Prilosec® comprising enteric coated pellets of omeprazole can only be administered through a tube after the content of the capsule has been dispersed in a buffering solution. Further, the product sold under the trade name Prevacid® Oral-suspension should not be given through tube according to the instruction from the manufacture.

10

Problems that might arise with administration of enteric coated pellets through gastric tube are for instance caused by the size of the enteric coating layered pellets and the inner diameter the tube or the outlet of the syringe, which might cause clogging in the syringe or tube. This is especially critical for pediatric patients where thin tubes are often required.

15 There is also a risk of reduced patient compliance and non-complete dose delivery because of pellets sediment in the glass and/or clogging the syringe used when preparing the suspension. This is especially critical in pediatric use when working with small volumes and doses.

20 In most cases, parental and /or injectable formulations are not viable alternative because of the need for administration to patients by people trained in medical care and in hospitals.

Therefore, it is still a demand for an improved method for oral administration and for development of new enteric coating layered multiple unit dosage forms that can be used for oral administration. The dosage forms intended for the new administration route should fulfil high demand with respect to chemical and mechanical stability during an extended storage time. Furthermore, there is still a demand for dosage forms having improved patient acceptance, which are easy to handle. One demand on solid dosage forms and compositions is that they should be dispersible in liquids making them possible for oral administration to young children and patients with difficulties to swallow.

30

Brief description of the invention.

One object of the present invention is to provide an improved method for administration via a gastric tube a composition comprising enteric coating layered pellets of a proton pump inhibitor, especially via thin tubes aimed for pediatric use. The expression gastric tube includes naso-gastric tubes as well as other tubes or syringes aimed for feeding a suspension or dispersion to the stomach of a patient.

According to one feature of the invention, the proton pump inhibitor is selected from the group of compounds such as omeprazole, lansoprazole, pantoprazole, rabeprazole or esomeprazole. According to a further feature the compound is esomeprazole prepared for oral administration, preferably as esomeprazole magnesium trihydrate in the form of enteric coating layered pellets. The dosage form comprises the prepared pellets in admixture with a pharmaceutical acceptable thickener. The thickener is capable of forming a viscous medium when dispersed in an aqueous carrier.

Another object of the present invention is to provide a solid composition, which comprises a proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets, the pellets are in mixture with one or more thickeners capable of forming a viscous medium when dispersed in an aqueous carrier. Prior to administration, a ready-to-use composition is prepared by mixing the solid composition of the pharmaceutically active proton pump inhibitor with an aqueous carrier.

It has surprisingly been found that the viscosity of the formed aqueous medium comprising dispersed enteric coating layered pellets of the active substance has an impact on the feeding of the suspension through a tube, such as a gastric or naso-gastric tube. It has been found that the higher viscosity the thinner tubes can be used within certain limits and the solid composition comprising a thickener facilitates and improves the administration, especially to young children. For instance, the handling instruction to patients can be simpler and the administration can be less time consuming.

Detailed description of the invention.


Active substance:

Compounds of interest for the improved method and composition of the present invention are compounds of the general formula I or an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof.




wherein


Het₁ is




or




Het₂ is




or




or



X =



or



wherein

N in the benzimidazole moiety means that one of the carbon atoms substituted by R₆-R₉ optionally may be exchanged for a nitrogen atom without any substituents;

5 R₁, R₂ and R₃ are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R₄ and R₅ are the same or different and selected from hydrogen, alkyl and aralkyl;

10

R₆' is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

R₆-R₉ are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxy carbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R₆-R₉ form ring structures which may be further substituted;






15






R₁₀ is hydrogen or forms an alkylene chain together with R₃ and

R₁₁ and R₁₂ are the same or different and selected from hydrogen, halogen or alkyl.

20 In the above definitions alkyl groups, alkoxy groups and moities thereof may be branched or straight C₁-C₉-chains or comprise cyclic alkyl groups, for example cycloalkylalkyl.

Examples of specifically interesting compounds according to formula I are





The active compound used in the claimed composition may be used in neutral form or in the form of an alkaline salt, such as for instance the Mg^{2+} , Ca^{2+} , Na^{+} or K^{+} salts, preferably the Mg^{2+} salts. The compounds may also be used in the form of one of its single enantiomers or alkaline salts thereof, such as exemplified in the second structural formula
5 above.

Preferred proton pump inhibitors for the claimed invention are for instance omeprazole, lansoprazole, pantoprazole, rabeprazole or a pharmaceutical acceptable salt thereof or a single enantiomer thereof, such as esomeprazole magnesium.
10

Some of the above mentioned compounds are for instance disclosed in EP-A1-0005129, EP-A1-174726, EP-A1-166287, GB 2163747, WO 94/27988, WO95/01977 and WO98/54171 all hereby incorporated by reference.

15 *Enteric coating layered pellets:*

Core material

The core material for the individually enteric coating layered pellets can be constituted according to different principles. Seeds layered with active substance, optionally mixed
20 with alkaline compounds, can be used as the core material for the further processing.

The seeds, which are to be layered with the active substance, can be water insoluble seeds comprising different oxides, celluloses, organic polymers and other materials, alone or in mixtures or water soluble seeds comprising different inorganic salts, sugars, non-pareils
25 and other materials, alone or in mixtures. Further, the seeds may comprise active substance in the form of crystals, agglomerates, compacts etc. According to one aspect of the invention the size of the seeds should be less than approximately 0.8 mm, preferably less than 0.4 mm. The seeds layered with active substance are produced either by powder- or solution/suspension layering using for instance granulating or spray coating/layering
30 equipment.

Before the seeds are layered, the active substance may be mixed with further components. Such components can be binders, surfactants, fillers, disintegrating agents, alkaline additives or other pharmaceutically acceptable ingredients, alone or in mixtures. The binders are for example celluloses such as hydroxypropyl methylcellulose, hydroxypropyl cellulose and carboxymethyl-cellulose sodium, polyvinyl pyrrolidone, sugars, starches and other pharmaceutically acceptable substances with cohesive properties. Suitable surfactants are found in the groups of pharmaceutically acceptable non-ionic or ionic surfactants such as for instance sodium lauryl sulfate.

Alternatively, the H^+K^+ -ATPase inhibitor or one of its single enantiomers or an alkaline salt thereof, optionally mixed with alkaline compounds and further mixed with suitable constituents can be formulated into core material. Said core materials may be produced by extrusion/spheronization, balling or compression utilizing different equipments. According to one aspect of the invention the size of the formulated core materials is approximately less than 1 mm and preferably in the range between 0.5 - 1 mm. The manufactured core materials can further be layered with additional ingredients comprising active substance and/or be used for further processing.

The active substance is mixed with pharmaceutical constituents to obtain preferred handling and processing properties and a suitable concentration of active substance in the final mixture. Pharmaceutical constituents such as fillers, binders, lubricants, disintegrating agents, surfactants and other pharmaceutically acceptable additives, can be used.

The active substance may also be mixed with an alkaline pharmaceutically acceptable substance (or substances). Such substances can be chosen among, but are not restricted to, substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; aluminium hydroxide/sodium bicarbonate coprecipitate; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as $Al_2O_3 \cdot 6MgO \cdot CO_2 \cdot 12H_2O$, $(Mg_6Al_2(OH)_{16}CO_3 \cdot 4H_2O)$, $MgO \cdot Al_2O_3 \cdot 2SiO_2 \cdot nH_2O$ or similar compounds; organic

pH-buffering substances such as trihydroxymethylaminomethane, basic amino acids and their salts or other similar, pharmaceutically acceptable pH-buffering substances.

Alternatively, the aforementioned core material can be prepared by using spray drying or
5 spray congealing technique.

Enteric coating layer(s)

Before applying enteric coating layer(s) onto the core material in the form of individual
10 pellets, said pellets may optionally be covered with one or more separating layers comprising pharmaceutical excipients optionally including alkaline compounds such as for instance pH-buffering compounds. This/these separating layer(s) separate(s) the core material from the outer layer(s) being enteric coating layer(s).

15 The separating layer(s) can be applied to the core material by coating or layering procedures in suitable equipments such as coating pan, coating granulator or in a fluidized bed apparatus using water and/or organic solvents for the coating process. As an alternative the separating layer(s) can be applied to the core material by using powder coating technique. The materials for separating layers are pharmaceutically acceptable compounds
20 such as, for instance, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methyl-cellulose, ethylcellulose, hydroxypropyl methyl cellulose, carboxymethylcellulose sodium and others, used alone or in mixtures. Additives such as plasticizers, colorants, pigments, fillers, anti-tacking and anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other
25 additives may also be included into the separating layer(s).

When the optional separating layer(s) is applied to the core material it may constitute a variable thickness. The maximum thickness of the optional separating layer(s) is normally only limited by processing conditions. The separating layer(s) may serve as a diffusion
30 barrier and may act as a pH-buffering zone. The pH-buffering properties of the separating layer(s) can be further strengthened by introducing into the layer(s) substances chosen from a group of compounds usually used in antacid formulations such as, for instance,

magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; composite aluminium/magnesium compounds such as, for instance $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$, $(\text{Mg}_6\text{Al}_2(\text{OH})_{16}\text{CO}_3 \cdot 4\text{H}_2\text{O})$, $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$, aluminium hydroxide/sodium bicarbonate coprecipitate or similar compounds; or other
5 pharmaceutically acceptable pH-buffering compounds such as, for instance the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, carbonic, citric or other suitable, weak, inorganic or organic acids; or suitable organic bases, including basic amino acids and salts thereof. Talc or other compounds may be added to increase the thickness of the layer(s) and thereby strengthen the diffusion barrier. The optionally
10 applied separating layer(s) is not essential for the invention. However the separating layer(s) may improve the chemical stability of the active substance and/or the physical properties of the novel multiple unit tableted dosage form.

One or more enteric coating layers are applied onto the core material or onto the core
15 material covered with separating layer(s) by using a suitable coating technique. The enteric coating layer material may be dispersed or dissolved in either water or in suitable organic solvents. As enteric coating layer polymers one or more, separately or in combination, of the following can be used; e.g. solutions or dispersions of methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl
20 methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylethylcellulose, shellac or other suitable enteric coating layer polymer(s).

The enteric coating layers contain pharmaceutically acceptable plasticizers to obtain the desired mechanical properties, such as flexibility and hardness of the enteric coating layers.
25 Such plasticizers are for instance, but not restricted to, triacetin, citric acid esters, phthalic acid esters, dibutyl sebacate, cetyl alcohol, polyethylene glycols, polysorbates or other plasticizers.

The amount of plasticizer is optimized for each enteric coating layer formula, in relation to
30 selected enteric coating layer polymer(s), selected plasticizer(s) and the applied amount of said polymer(s), in such a way that the mechanical properties, i.e. flexibility and hardness of the enteric coating layer(s) are adjusted. Additives such as dispersants, colorants,

pigments, polymers e.g. poly(ethylacrylat, methylmethacrylat), anti-tacking and anti-foaming agents may also be included into the enteric coating layer(s). Other compounds may be added to increase film thickness and to decrease diffusion of acidic gastric juices into the acidic susceptible material.

5

To protect an acidic susceptible substance, such as H^+K^+ -ATPase inhibitors and to obtain an acceptable acid resistance of the multiple unit dosage form according to the invention, the enteric coating layer(s) constitutes a thickness of approximately at least 10 μm , preferably more than 20 μm . The maximum thickness of the applied enteric coating layer(s) is normally only limited by processing conditions.

10

Over-coating layer

15

Pellets covered with enteric coating layer(s) may further be covered with one or more over-coating layer(s). The over-coating layer(s) can be applied to the enteric coating layered pellets by coating or layering procedures in suitable equipments such as coating pan, coating granulator or in a fluidized bed apparatus using water and/or organic solvents for the layering process. The materials for over-coating layers are pharmaceutically acceptable compounds such as, for instance sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium and others, used alone or in mixtures. Additives such as plasticizers, colorants, pigments, fillers, anti-tacking and anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other additives may also be included into the over-coating layer(s). Said over-coating layer may further prevent potential agglomeration of the enteric coating layered pellets and protect the enteric coating layer from incompatible excipients or pH values above its dissolution pH, e.g. during the preparation of the suspension, administration and swallowing. The over-coating layer may also include a taste-masking agent. The maximum thickness of the optionally applied over-coating layer(s) is normally only limited by processing conditions.

30

Pharmaceutically acceptable thickener:

Thickeners suitable for the composition of the present invention are thickeners generally used in food industry, such as starch, carrageenan, xanthan gum, guar gum, locust bean gum, tragacanth, gelatin, pectin, modified cellulose derivatives or similar gel forming agents. One single thickener or a combination of thickener can be used.

Alternatively, the enteric coated pellets comprising the pharmaceutically active ingredient may be mixed with a viscous medium such as yoghurt, syrup, sour milk or any aqueous liquid with a similar viscosity. The viscous medium formed or used will provide a homogenous suspension/dispersion to allow the enteric coated pellets floating in the medium.

If no protective over-coating layer is applied on the enteric coating layered pellets the pH value of the viscous medium would be adjusted so that the enteric coating of the pellets is not destroyed during the administration and preparation of the aqueous suspension or dispersion of pellets in the viscous medium, i.e. the enteric coating polymer should not be dissolved in the viscous medium. According to one aspect of the invention, the pH value of the viscous medium is approximately less than 7 and preferably less than 5.6.

The thickener may be mixed with suitable flavour and colour agents and/or sweetening agents acceptable for food products.

It has surprisingly been found that the higher viscosity of the aqueous medium being formed or used for the dispersion/suspension of the enteric coating pellets the narrower gastric tubes can be used.

According to one feature of the invention, the commercial available thickener sold under the trade name "Thick-It" comprising maize starch has shown to be suitable for the improved method for administration via gastric tube. According to another feature, the viscous medium could be yoghurt, syrup or sour milk.

According to one aspect of the invention, the viscosity of the formulation after gelation should be 0.005 – 10 Pa s and preferably 0.05 – 5 Pa s, as determined at a shear rate of 10 s⁻¹ from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.

Alternatively, the viscosity can be expressed as amount of thickener with respect to amount of aqueous liquid.

Suitable aqueous carriers or liquids to use for administration of the composition through a gastric tube are water, and other pharmaceutically acceptable carriers for oral administration such as fruit juices, dairy products such as milk. Alternatively, the aqueous carrier as such can be used as viscous medium, such as sour milk, yoghurt and liquids with similar viscosity.

The amount of administered aqueous carrier/liquid depends on the amount of active substance, but will generally be in the range of 1 – 50 mL, preferably 1 – 30mL.

Gastric tubes:

Gastric tubes includes naso-gastric tubes as well as tubes and syringes for feeding. Tubes suitable for the improved method of administration are tubes made of polyvinyl cellulose, polyurethan and similar materials. The size of the tube can vary depending on the patients and the purpose. Adults with swallowing disorders can use tubes with a size measured as CH =Cherrier or "French size" with an inner diameter of approximately CH14 – CH20.

Suitable size for pediatric use is approximately a size of CH5 – CH10, such as CH5, CH6 and CH8.

Use of composition.

The composition according to the invention is used for reducing gastric acid secretion. It can be administered one to several times a day. The typical daily dose of the active substance varies and will depend on various factors such as the individual requirements of the patients, the mode of administration and disease. In general the daily dose will be in the

range of 1-100 mg of active substance, in some severe cases such as Zollinger-Ellison syndrome there might be a need for higher doses. Preferred doses for adults are 10 – 80 mg and for pediatric use the preferred doses are 0.5 – 40 mg of active substance, and for the youngest 0.5 – 20 mg depending on the severity.

5

The present invention is further described and exemplifies in the following experimental report without limiting the invention. The scope of protection is defined by the accompanying claims.

10 *Experimental report.*

Equipment:

Luer lock TM syringe: 30mL.

Tube: PennineTM health care, Ref No. 15E00; 020E01 (CH 8); 13B01 (CH 10)

FlocareTM Pure tube, Ref No. 35242 (CH 6)

15 Argyle Salem Sump TM (CH 10)

Graduated glass: 100mL

Thickener: Thick-ItTM

Preparation of enteric coated pellets:

20 Esomeprazole magnesium trihydrate was prepared according to US 6,369,085. The prepared active ingredient was formulated into enteric coated pellets as described in US 5,817,338, and the prepared pellets were mixed with the prepared viscous media. The content of US 6,369,085 and US 5,817,338 are hereby incorporated by references.

25 Preparation of medium:

Different amounts of Thick-It TM (5, 6, 7 and 8 g, respectively) were mixed with 100 mL tap water, the aqueous solution was mixed vigorously for approx. 1 minute. Prepared enteric coated pellets comprising esomeprazole Mg, corresponding to 10 mg esomeprazole were mixed with 10mL of the different aqueous, viscous media prepared. The different
30 suspensions were feeded through different tubes.

Pure tap water without thickener was used as reference medium.

The tubes were tested according to the following procedure:

5 The tubes were flushed with some water before administration.

1. Remove the piston from a 25-50 mL syringe (Luer-Lock, 30 mL is used) and fill the syringe with approximately 25 mL water.
2. Empty the content of the capsule in the syringe and put the piston back. Leave a
10 space of approximately 5 mL air.
3. Immediately shake the syringe for approximately 15 seconds to disperse the pellets.
4. Hold the syringe with the tip up and check that the tip has not been clogged.
5. Attach the syringe to the tube whilst maintaining the above position (tip pointing up).
- 15 6. Shake the syringe and position it with the tip pointing down. Immediately inject 5-10 mL into the tube. Invert the syringe after injection and shake (the syringe must be held with the tip pointing up to avoid clogging of the tip). Turn the syringe with the tip down and immediately inject another 5-10 mL into the tube. Repeat this procedure until the syringe is empty.
- 20 7. Fill the syringe with 25 mL of water and 5 mL of air and repeat step 6 if necessary to wash down any sediment left in the syringe.

Result:

When comparing results from the testing of media with and without thickener, pellets
25 could be administered through more narrow tubes without clogging the tubes when using viscous media for feeding than when using pure tap water. In this experiment, optimal viscosity was obtained when using 6 – 7 g Thick-It™ in 100 mL tap water.

CLAIMS:

1. A method for oral administration via a gastric tube of a solid composition comprising an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating
5 layered pellets in a medium, wherein the pellets are in admixture with one or more pharmaceutically acceptable thickeners capable of forming a viscous medium when dispersed in an aqueous carrier and the formed aqueous suspension is administered through a gastric tube or syringe to a patient in need of such a treatment.
- 10 2. The method according to claim 1, wherein the thickener is selected from the group of starch, xanthan gum, carrageenan, guar gum, locust bean gum, tragacanth, gelatin, pectin and modified cellulose derivatives alone or in any combination.
3. The method according to claim 1, wherein the thickener is selected from starch and
15 xanthan gum.
4. The method according to claim 1, wherein the composition in addition comprises pharmaceutically acceptable additives selected from flavouring agent, colour agent and sweetening agent.
- 20 5. A method for oral administration via a gastric tube of a composition comprising an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets in a medium, wherein the medium is a pharmaceutically acceptable viscous medium in which the pellets are dispersed to an aqueous suspension and administered
25 through a gastric tube or syringe to a patient in the need of such treatment.
6. The method according to claim 5, wherein the viscous medium is selected from yoghurt, syrup and aqueous liquids with a similar viscosity.

7. The method according to any of claims 1 and 5, wherein the viscosity of the formulation after gelation should be 0.005 – 10 Pa s, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
- 5 8. The method according to any of claims 1 and 5, wherein the viscosity of the formulation after gelation should be 0.05 – 5 Pa s, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
9. The method according to any of claims 1 and 5, wherein the aqueous suspension is
10 administered through tubes with the size CH 5 to CH 10 (CH= Cherrier).
10. The method according to any of claims 1 and 5, wherein the aqueous suspension is administered through tubes with the size CH10 to CH20 (CH= Cherrier).
- 15 11. The method according to any of claims 1 and 5, wherein the proton pump inhibitor compound is selected from the group of compounds known under the generic names omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole.
12. The method according to any of claims 1 - 5, wherein the amount of administered
20 active substance is 1 – 100 mg.
13. The method according to claim 1, wherein the aqueous carrier is selected from the group of water, fruit juice, syrup and dairy products.
- 25 14. The method according to any of claims 1 -5, wherein the amount of administered viscous medium is approximately 1 – 35 mL.
15. Solid composition comprising a proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets, wherein the pellets are in admixture with one or

more thickeners capable of forming a viscous medium when dispersed in an aqueous carrier.

16. A composition according to claim 15, wherein the enteric coated pellets have a size of
5 less than 1 mm.

17. Use of a thickener in the preparation of a composition for oral administration through
a gastric tube wherein the composition comprises an acid labile proton pump inhibitor in
the form of a multiple of enteric coating layered pellets in a medium and the thickener is
10 capable of forming a viscous medium when dispersed in an aqueous carrier.

18. Use of a viscous medium in the preparation of a composition for oral administration
through a gastric tube wherein the composition comprises an acid labile proton pump
inhibitor in the form of a multiple of enteric coating layered pellets and the pellets are
15 dispersed in the viscous medium to an aqueous suspension.

ABSTRACT.

The present invention related to a method for oral administration of a solid composition comprising an acid labile proton pump inhibitor compound in the form of a multiple of
5 enteric coating layered pellets, wherein the pellets are in admixture with one or more pharmaceutically acceptable thickeners capable of forming a viscous medium when dispersed in an aqueous carrier. Alternatively, the enteric coated pellets are in admixture with a viscous medium. The formed aqueous viscous suspension is administered through a gastric tube. The method and composition are especially aimed for treatment of patients in
10 need of a proton pump inhibitor and having difficulties to swallow or for pediatric patients.